# Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough

> **NCT04318704** · PHASE2 · COMPLETED · sponsor: **Algernon Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Ifenprodil

## Key facts

- **NCT ID:** NCT04318704
- **Lead sponsor:** Algernon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-29
- **Primary completion:** 2022-05-10
- **Final completion:** 2022-05-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04318704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04318704, "Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04318704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*